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Dr Tirone E. David (Toronto, Ontario, Canada). Dr Suri and
his colleagues fromMayoClinic are to be commended for carrying
out this prospective, randomized trial on early hemodynamic per-
formance of 3 currently used bioprosthetic valves for AVR. Hemo-
dynamic assessment of bioprosthetic valves a few days after
implantation may not represent the final hemodynamic result of
the bioprosthesis at 6 months or 1 year, and I hope Dr Suri will
bring his patients back and tell us next year what happened to those
gradients and the aortic valve sizes. Our specialty certainly needs
more randomized controlled trials whenever possible, and choicediovascular Surgery c Volume 144, Number 6 1395
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Dof bioprosthetic valve for AVR is one of those areas. Dr Suri and
colleagues’ randomized trial showed that the mean gradient across
the aortic valve was approximately 16 mmHg for Epic, 14 mmHg
for Magna, and 16 mm Hg for Mitroflow for the entire cohort of
patients, and these values were statistically different with a P value
of .01. Similarly, the aortic valve areas were 1.86 cm2 for Epic,
2.05 cm2 for Magna, and 1.88 cm2 for Mitroflow, and the differ-
ences were again statistically significant. And so were the indexed
orifice areas. My first question to you, Rakesh: Is there clinical rel-
evance in these differences? In other words, do you believe that
a mean gradient of 14 mm Hg or 16 mm Hg has any clinical
consequence?
Dr Suri. Thank you, Dr David, for those comments. We do not
currently believe that these small differences in transprosthetic
gradient have clinical relevance during the early postoperative pe-
riod. Cognizant of the fact that the perioperative changes in car-
diac output caused by catecholamine elevations, anemia, and
increased stroke volume early after surgery may temporarily ele-
vate the transprosthetic gradient, we further analyzed the flow-in-
dependent measures of valve performance such as uncorrected
AVA and AVAi. These comparisons also showed only very small
differences among devices. It is interesting to note that there
were slight variances in the outcome of the comparative analyses
depending on whether data were stratified by implant size or ac-
tual annular size. Our European colleagues have written about
these varying methods of analysis, stressing the importance of nor-
malizing hemodynamic data by actual annular size to account for
differences in commercial valve labeling. What is striking is that
when we controlled for discrepancies in commercial size labeling,
many of the differences among devices disappeared and the per-
formance of the 3 valves over a range of directly measured univer-
sal annulus sizes was quite similar. Finally, our randomized
cohorts are scheduled for clinical and echocardiographic follow-
ups at 1 year and 5 years. We are currently seeing patients for their
1-year visit. We look forward to presenting these data in the
future.
Dr David. Patient–prosthesis mismatch is really what we
should try to avoid during AVR, particularly in patients who are
physically very active or have impaired LV systolic function.
Your trial showed that the average aortic valve index was around
1 cm2/m2 in all 3 groups of patients, and I commend you again
for trying to implant the largest possible valve to avoid patient–
prosthesis mismatch. However, your surgeons had to patch enlarge
the annulus in approximately 10% of your patients. Because the
randomization was done after the patch enlargement, patch en-
largement did not affect the outcomes, but it did bias the result
on the hemodynamic performance of the valves. My next question
to you is related to the fact that, although Magna showed the best
hemodynamic performance, it also had the highest incidence of
annular enlargement and also the highest incidence of mismatch.
Although the differences were not statistically significant, they
are, however, significant for the average surgeon who doesn’t do
this operation every day.
Dr Suri. Those are important considerations. To address your
first point, when designing the trial protocol, we thought about
surgical strategy in the following way. Assuming hemodynamic
equipoise among devices, we wanted to understand the implica-
tions of placing each of the 3 valves in a given annular orifice.1396 The Journal of Thoracic and Cardiovascular SurWe thus left it to the surgeon to perform an a priori assessment
of whether aortic annular enlargement would first be required
based on the estimated physiologic needs of the patient. What
is reassuring is that all valves performed similarly well using
this strategy, and the frequency of annular enlargement was com-
parable among groups. The specific question regarding who en-
larges the aortic annulus is more complicated, and this study
does not address that issue. These data indicate, however, that
regardless of the valve type placed in a small aortic annulus,
flow-dependant and -independent performance of the devices
were indistinguishable statistically. Last, these data could also
be interpreted to imply that in those with LV dysfunction, or
who require maximization of postoperative AVA, annular en-
largement is required. In other words, merely selecting a different
prosthesis for a given annular dimension will not necessarily pro-
vide a significant increase in postoperative indexed orifice area.
An interesting point to note in the data provided by the 3 compa-
nies themselves, which detail differences in dimensions of the 3
devices, are actual external valve size measurements. The Mitro-
flow valve has the smallest external diameter footprint, yet the
valve performed very similarly to those with larger internal and
external diameters. Finally, I will try to address your point on
patch closure of the aortic root. To clarify, 4% of patients under-
went patch enlargement of the aortic annulus and 10% had patch
closure of the aortic root only. Despite the fact that the Magna
valve is intermediate in external diameter and stent height be-
tween the 2 groups, the question is why surgeons slightly more
frequently used a bovine pericardial patch to close the aortic
root. Many of you will have your own suspicions regarding differ-
ences in stent characteristics; however, this study was not de-
signed to draw definitive conclusions on that topic.
Dr David. Finally, if the hemodynamic performance of differ-
ent porcine and pericardial valves is similar, surgeons should
have to consider the durability of the bioprosthetic valve when
matching the patient to the type of valve. One should not implant
a valve only because it has excellent hemodynamic performance. I
would like to thank The American Association for Thoracic Sur-
gery for the privilege of discussing this paper.
Dr Suri. Thank you again, Dr David. That is a very important
point. Dr David has recently published a seminal paper on long-
term durability of biologic aortic valve prostheses and I encourage
those of you who haven’t read it to do so. The current study, Dr Da-
vid, reflects the first step in our planned long-term follow-up of
these patients. We hope to comment both on mid- and long-term
durability of these devices in the future.
Dr Lawrence H. Cohn (Boston, Mass). I have a question about
the patch enlargement. I have always been fascinated with this.
The mean age of your group was 76 years of age and yet you patch
enlarged 10%, or 30 of the patients. Could you give us a feel for
what kind of patient you are enlarging at this age group? A lot
of these patients in my practice are elderly women—80 years
old—and all they want to do is walk down the mall with their
grandchildren, so we put in 19-mm and 21-mm valves quite fre-
quently. I am would be curious as to what kind of patients were
patched in this age group.
Dr Suri. That is a very interesting question, Dr Cohn. As you
are aware in your own practice, we all do things slightly differ-
ently and thus have varying predispositions toward enlargementgery c December 2012
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Dof the aortic annulus. Cardiac surgeons all seek to avoid severe
patient–prosthesis mismatch; some use charts and other clinical
judgment based on accrued surgical experience. Further, there is
general agreement that severe mismatch is particularly problem-
atic in those who are active or who have preoperative LV
dysfunction, and thus at Mayo Clinic we would be particularly
aggressive in enlarging the annulus of these patient subsets, as
we did in 4% of the current study population. We are not sug-
gesting that cardiac surgeons should be enlarging the annulus
of all patients, particularly as you point out, in those who are
frail and merely require amelioration of severe calcific AS to re-
store their quality of life with limited requirement for physical
activity.
Dr Rohit Shahani (Poughkeepsie, NY). Thank you for a nice
paper. When we talk about small sizes in the aorta, could you
tell us in absolute numbers how many of the valves you put in
were 19?
Dr Suri. Fourteen valves of size 19 were implanted overall: 3
Epic, 6 Magna, and 5 Mitroflow.
Dr Robert A. Dion (Genk, Belgium). Don’t you think that,
based on your findings, one still can make a decision about using
a very small size? I have the impression that 1 of the 3 is doing bet-
ter in gradients and in areas. Also, if one is confronted with a very
small annulus and is being forced to insert<size 21, what would
you do?Would you carry on enlarging the aortic root or would you
go, for instance—what I am doing—for a full-root supra-annular
stentless valve? Thank you.
Dr Suri. Thank you, Dr Dion. Those are good questions. The
first point I will address is your last question, and I concur with
the perspective of Dr Cohn on this; severe aortic stenosis patients
with a normal ventriclewho are small, elderly, frail, and have a nor-
mal ventricle can do very well with a no. 19 valve in the absence of
severe mismatch. Notably, our data suggest that all valves studied
in this randomized series performed equally well, with a low fre-
quency of PPM in patients with a small aoric annulus. As is the
case with most surgical decisions in our specialty, a thoughtful
analysis of advantages and disadvantages as related to the specific
clinical scenario in each patient is warranted. Additionally, we do
not typically implant stentless valves or routinely enlarge the aor-
tic annulus in small, frail, elderly patients unless there is predicted
physiologic need based on individual clinical circumstances. The
other question, as I understand it, is regarding the small hemody-
namic differences noted between the combined commercial sizes
nos. 19 and 21 groups. As I mentioned, longitudinal follow-up
will be essential to track these 3 well-matched randomized subsets
over time. Although one may speculate regarding potential late
outcomes, we cannot currently conclude that there are clinicallyThe Journal of Thoracic and Carmeaningful hemodynamic differences among any of the random-
ized valve groups during the early postoperative period.
Dr Guo-Wei He (Tianjin, China). I feel this is a very important
study from the Mayo Clinic. Now, our practice pattern in China is
different from your practice in the Mayo Clinic. In my own prac-
tice, up to 50% of the patients are still the result of rheumatic
heart disease; another 50% are attributed to another etiology
such as degeneration or infection. I have a question related to pa-
tients between the ages of 60 years and 65 years. In this situation,
we may put either a bioprosthesis or a mechanical valve in. I
would like to know, in the Mayo Clinic experience, as far as
the hemodynamic effect is concerned, in this age group, which
valve prosthesis would you use? A bioprosthesis or a mechanical
valve?
Dr Suri. This is a very interesting question. There are 2 factors
we discuss we consider when helping patients decide between
mechanical versus biological valve substitutes in the so-called
gray zone. The first, as you said, is hemodynamic performance.
In the current era with novel, third-generation biologic devices,
the hemodynamic differences between mechanical and biologic
devices are not large, and thus this seldom is the most influential
factor in determining prosthesis choice. The second point is an
important and less well understood concept—the late potential
survival difference between valve types. There is a growing
body of evidence to suggest that there may be a long-term survival
advantage associated with implantation of a mechanical versus
a biologic aortic valve in risk-matched middle-aged patients. Of
course, the opposing argument would be that the quality-of-life
implications of oral anticoagulants are more influential on pros-
thesis choice. However, that debate is beyond the scope of the dis-
cussion today. We currently have a manuscript submitted that
addresses the late prognostic implications of mechanical versus
biologic aortic valve replacement and we hopefully will have
more to share on the topic in the near future. Ultimately, patients
at Mayo Clinic undergoing preoperative assessment for valve re-
placement are thoroughly informed of indications, risks, benefits,
and alternatives before selecting an appropriate prosthetic valve
substitute.
Dr Joseph Ladowski (Ft. Wayne, Ind). Dr Suri, not an elegant
question, but a practical one. If you yourself needed one of these
valves tomorrow, which one do you want?
Dr Suri. For the sake of maintaining equipoise as the principal
investigator of this study, and as the data have confirmed is war-
ranted at the current time in light of small differences between
the valves studied in this trial, I am going to politely defer that
question. I thank The American Association for Thoracic Surgery
for the opportunity to present our data today.diovascular Surgery c Volume 144, Number 6 1397
